A guided first visit
What do you want to know about living healthier for longer?
Choose an orientation path or begin with a familiar outcome. Every path contains four already-published reads, and the reason for each step is visible.
Compare all 55 stories in the Human Longevity Evidence TrackerNew evergreen guide
Start with the foundations before the hacks
10 things you can do for a longer, healthier life separates clinical outcomes, function and risk-factor evidence from claims about slower aging or added lifespan.
Learn the map
From first principles to real interventions
Begin with the field, an everyday category, drugs and supplements, or experimental translation.
Path 01
New to longevity science
Learn the map, then practice separating evidence maturity from a headline.
- Start
What is longevity research?
Start with the vocabulary and the layers that connect a result to a reader-facing claim.
Orientation guide · Field map and core distinctions - Next
How strong is the evidence?
Next, see why a mechanism, biomarker, association and clinical outcome answer different questions.
Evidence guide · Cells, animals, human studies and outcomes - Then
Exercise and healthy aging
Apply those distinctions to a mature human evidence base without turning broad benefit into a lifespan guarantee.
Evidence explainer · Human function, disease risk and mortality - Compare
Partial reprogramming reaches a human safety trial
Finish by contrasting that mature evidence with a genuinely experimental program.
Research analysis · Early human safety testing and animal evidence
Path 02
Everyday life
Move from a broad category to studies of exercise, mobility and eating patterns.
- Start
Everyday foundations
Start with the complete category so a single study does not stand in for the whole evidence base.
Topic hub · Exercise, sleep and eating patterns - Next
Exercise and healthy aging
See the broad human evidence and the boundary between healthier aging and proven lifespan extension.
Evidence explainer · Human function, disease risk and mortality - Then
Physical activity and late-life mobility
Narrow the question to one randomized program and one concrete functional outcome.
Research analysis · Mobility disability in at-risk older adults - Compare
The randomized MIND diet trial
Compare a different everyday intervention where the active control changed what the result means.
Research analysis · Human cognition and MRI outcomes
Path 03
Drugs & supplements
Compare null, mixed and early signals without treating category membership as endorsement.
- Start
Drugs & supplements
Start with the category boundaries, safety notes and complete released coverage.
Topic hub · Seventeen published evidence reviews - Next
Omega-3 cardiovascular evidence
See why results from unlike formulations and populations should not be collapsed into one verdict.
Evidence explainer · Different formulations and cardiovascular outcomes - Then
Vitamin D and the VITAL trial
Separate an essential nutrient and deficiency care from a broad prevention claim.
Claim check · Primary prevention in generally healthy adults - Compare
Rapamycin and the PEARL trial
Finish with an intervention whose human longevity evidence remains early and limited.
Research brief · Small human feasibility and safety trial
Path 04
Experimental science & aging measurements
Follow the translation chain from models and measurements to bounded human claims.
- Start
From models to people
Start with the questions that determine whether a model result can transfer to people.
Translation guide · Cells, organisms, exposure, outcomes and safety - Next
How to read an aging biomarker
Then separate a measurable change from a validated health outcome.
Measurement guide · Validity, surrogacy, function and lifespan - Then
Partial reprogramming reaches a human safety trial
Apply the translation questions to an experimental biotechnology entering human study.
Research analysis · Early human safety testing and animal evidence - Compare
What epigenetic clocks can—and cannot—measure
Finish with a measurement story where prediction and proven intervention benefit remain distinct.
Evidence explainer · Human aging biomarkers
Start with an outcome
Start with the outcome you care about
These sequences keep unlike outcomes and study designs separate. Position shows reading order only.
Path 05
Heart and circulation
Compare cardiovascular events, mortality and prevention settings without turning one result into a universal recommendation.
- Start
SPRINT reduced cardiovascular events—not aging itself
Start with a trial that measured cardiovascular events and mortality in a defined high-risk population while also recording treatment harms.
Research Analysis · Human clinical outcomes · large randomized trial - Next
ASPREE did not lower cardiovascular events—and increased major bleeding
Compare a different primary-prevention population where the cardiovascular result was null and major bleeding increased.
Evidence Explainer · Human cardiovascular and safety outcomes · large randomized trial - Then
Statin evidence changes with age, risk and prevention setting
Then see why primary versus secondary prevention, age and baseline risk change what the evidence can support.
Evidence Explainer · Human clinical outcomes · trials and pooled evidence - Compare
Menopausal hormone therapy treats symptoms. WHI did not show a longevity benefit
Finish with a long mortality follow-up that keeps symptom treatment, disease outcomes and general longevity prevention separate.
Research Analysis · Human disease outcomes and mortality · randomized trials
Path 06
Brain and cognition
Keep cognitive tests, dementia outcomes and subgroup findings in their proper lanes.
- Start
FINGER slightly improved cognitive-test scores. It did not prove dementia prevention
Start with a randomized cognitive-test result and the boundary between a measured score and dementia prevention.
Research Analysis · Human cognitive tests · randomized multidomain trial - Next
Cognitive training improved practiced skills—not survival or proven dementia prevention
Compare practiced abilities with disputed secondary dementia findings and a separate null mortality result.
Evidence Explainer · Human trained abilities and long-term outcomes · randomized trial plus disputed secondary analysis - Then
Shingles vaccines prevent shingles. Dementia evidence remains non-randomized
Next, separate randomized evidence for shingles prevention from non-randomized evidence about dementia outcomes.
Research Analysis · Human disease outcomes · randomized and non-randomized evidence - Compare
Hearing intervention did not slow cognitive decline across the full ACHIEVE trial
Finish with a null overall cognitive result whose higher-risk subgroup signal requires confirmation.
Research Analysis · Human outcomes · randomized trial with subgroup signals
Path 07
Strength, bones and independence
Separate bone density, fractures, mobility disability and physical-function tests.
- Start
Testosterone did not prevent fractures in TRAVERSE
Start by seeing why a bone-density change cannot substitute for the clinical fracture outcome.
Evidence Explainer · Human fracture and bone-density outcomes · randomized trials - Next
Zoledronic acid reduced fractures in osteoporosis—not aging itself
Compare an osteoporosis trial that measured vertebral and hip fractures directly while retaining population and safety limits.
Research Analysis · Human fracture outcomes · large randomized trial - Then
Structured physical activity reduced late-life mobility disability—not aging itself
Move from bone outcomes to a concrete mobility-disability result in vulnerable older adults.
Evidence Explainer · Human function · randomized trials - Compare
Testosterone’s walking result was modest—not an anti-aging effect
Finish with a walking-test result where subgroup and secondary analyses do not establish broader independence or longevity.
Claim Check · Human physical-function outcomes · one-year randomized trials